Buffett Back at the Buy Window, Plus Insider Buying at a Refiner, Biotechs, and More 24/7 Wall St. 3 days
Sarepta Therapeutics’ stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug MarketWatch 5 days
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win Investor's Business Daily 1 week
Zal Bilimoria just raised a $50M fourth Refactor Capital fund, and still relishes his solo GP status TechCrunch 1 week
Nurix Therapeutics, With 345% Run, Posts A ‘Clear Win’ In Leukemia Treatment Investor's Business Daily 1 week
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. The Motley Fool 1 week
The ‘Impressive’ Results That Sent Top 1% Avidity Biosciences To A Record Investor's Business Daily 2 weeks
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet Investor's Business Daily 2 weeks
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst Seeking Alpha 2 weeks
The Biotech Company Trying to Win FDA Approval to Treat PTSD With MDMA Just Got Some Bad News Inc.com 3 weeks
